NPM1 gene mutations in children with Myelodysplastic syndromes by Jekić, Biljana et al.
Arch. Biol. Sci., Belgrade, 63 (3), 649-653, 2011 DOI:10.2298/ABS1103649J
649
NPM1 GENE MUTATIONS IN CHILDREN WITH MYELODYSPLASTIC SYNDROMES
BILJANA JEKIC1, VERA BUNJEVACKI1, VALERIJA DOBRICIC2, IVANA NOVAKOVIC1,  
JELENA MILASIN3, BRANKA POPOVIC3, TATJANA DAMNJANOVIC1, NELA MAKSIMOVIC1,  
V. PEROVIC4 and LJILJANA LUKOVIC1
1 Institute of Human Genetics, School of Medicine, 11000 Belgrade, Serbia 
2 Institute of Neurology, Clinical Centre of Serbia, 11000 Belgrade, Serbia 
3 Institute of Biology and Human Genetics, School of Dentistry, 11000 Belgrade, Serbia 
4 Institute for Mother and Child, 11000 Belgrade, Serbia
Abstract - Myelodysplastic syndromes (MDS) are rare in children and only a few studies have analyzed their molecular 
mechanisms. The NPM1 gene encodes for nucleophosmin (NPM) which regulates hematopoiesis. Mutations in exon 12 of 
the NPM1 cause the nucleophosmin cytoplasmic dislocation and disrupt its functions. We have analyzed mutations of the 
NPM1 gene in archival bone marrow samples from 17 children with MDS and detected, in one patient, transition C to T 
in codon 293. To the best of our knowledge, this is the first analysis of NPM1 mutations in childhood MDS and the very 
first missense mutation of the NPM1 gene reported so far.
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INTRODUCTION
Myelodysplastic syndromes (MDS) are a hetero-
geneous group of clonal disorders of the multipo-
tent hematopoietic progenitor cell. MDS are rare in 
childhood and there are only a few studies analyzing 
the molecular mechanisms underlying these severe 
diseases. 
Nucleophosmin (NPM) is an essential protein 
for the regulation of hematopoiesis. NPM1+/- het-
erozygous mice develop a hematological disorder 
with features of human myelodysplastic syndromes 
(Grisendi et al., 2005).
NPM is a highly conserved multifunctional 
phosphoprotein predominantly localized in the 
nucleolus. Nucleophosmin acts as a molecular 
chaperone, facilitates the transport of ribosom-
al proteins through the nuclear membrane and 
regulates the stability of various nuclear proteins 
(Chen et al., 2006). Additionally, the control of 
centrosomal duplication during the cell cycle and 
modulation of the activity of tumor-suppressors 
such as p53 (Colombo et al., 2002) are also attrib-
uted to NPM. 
Mutations in exon 12 of the NPM1 gene that 
cause the cytoplasmic dislocation of protein repre-
sent the most frequent genetic alterations in adult 
patients with karyotypically normal acute myeloid 
leukemia (Chou et al., 2006; Thiede et al., 2006). 
MDS are referred to as preleukemias, because 
of their tendency to transform into acute myeloid 
leukemia (AML). Consequently, findings obtained 
from studies on AML patients may serve as a clue for 
molecular genetic analyses in MDS. 
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The aim of our study was to investigate the prev-
alence and the type of NPM1 gene mutations in a co-
hort of Serbian children with MDS. 
MATERIALS AND METHODS
Bone marrow samples
We analyzed archival bone marrow samples from 17 
children (14 boys and 3 girls) with MDS, diagnosed 
and treated at the Belgrade Institute for Mother 
and Child Health of Serbia. The diagnosis and the 
type of MDS were established according to the FAB 
(French–American–British) criteria and bone mar-
row histology data after the exclusion of other causes 
of myelodysplasia.
The study was approved by the Ethical Com-
mittee of the School of Medicine, University of Bel-
grade. 
Conventional cytogenetic investigations were per-
formed by standard procedures and data were avail-
able for 10 patients. Seven patients showed karyotype 
abnormalities while three had normal karyotypes. 
Five of the seven patients had a single karyotype ab-
normality: chromosome 7 monosomy; chromosome 
19 monosomy; t(3;5)(q23;q32); inv(9) (p11q13) and 
del(9)(p13), respectively. In the remaining two pa-
tients complex karyotypic abnormalities were ob-
served (46,XY/46,XY del(12)(q22), del(5)(q12q13) 
and 44,XY del(5) del(7) del(11)-17,-18).
Five of the 17 MDS patients developed leukemia 
and four of them were from the group with karyotype 
abnormalities. Further progression of karyotypic 
complexity during the evolution to leukemia was not 
observed. Three of the five patients who developed 
leukemia, according to the FAB criteria, were clas-
sified as refractory anemia, refractory anemia  with 
excess of blasts and refractory anemia  with excess of 
blasts in transformation. The remaining two patients 
could not be classified at the time of diagnosis. 
Genomic DNA was isolated from archival bone 
marrow smears using the standard phenol-chlo-
roform method. Control DNA was taken from the 
blood of healthy volunteers.
PCR – SSCP analysis
For the screening of NPM1 gene exon 12 mutations 
by the PCR-SSCP (polymerase chain reaction – sin-
gle strand conformation polymorphism) method, we 
created primers flanking the region of interest. The 
forward and reverse primers were 5’- TGT-CTA-
TGA-AGT-GTT-GTG-GTT-CC- 3’ and 5’- GCA-
TTA-TAA-AAA-GGA-CAG-CCA-GA-3’, respec-
tively. PCR amplifications were performed under 
the following conditions: initial denaturation at 950C 
for 5 min; 35 cycles of denaturation at 950C for 30 
s, annealing at 640C for 45 s, extension at 720C for 1 
min and final extension at 720C for 7 min. The PCR 
products were 179 bp long. The SSCP method was 
performed according to the standard procedure. 
Direct sequencing
To confirm the results obtained by the PCR-SSCP 
method and to determine the type of mutation de-
tected, we performed sequence analyses using the 
previously described primers. The PCR products 
were purified and directly sequenced using the ABI 
Ready Reaction Dye Terminator Cycle Sequencing 
Kit (Applied Biosystems). 
RESULTS
PCR-SSCP analysis
According to PCR-SSCP analysis, the sample of one 
MDS patient showed a distinct pattern of mobility 
through polyacrylamide gel. 
Sequence analysis
The sequence analyses confirmed that the patient 
previously indicated by the SSCP method as a car-
rier of mutation harbors transition T to C that 
results in the exchange of serine to proline in the 
WQWRKSL amino acid sequence of the NPM pro-
tein (Fig. 1). 
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Prediction of mutation effect
Three prediction methods were used to determine 
whether an amino acid substitution would af-
fect protein function: the SIFT prediction method 
(http:// sift.jcvi.org/www/ SIFT_seq_submit2.html) 
(Ng and Henikoff, 2003), the PolyPhen program 
(http://www.bork.embl-heidelberg.de/PolyPhen/) 
(Ramensky et al., 2002) and the PMut program 
(http://mmb2.pcb. ub.es:8080/PMut ) (Ferrer-Cos-
ta et al., 2005). 
All prediction methods revealed that the substi-
tution of S293P at the C - terminus of NPM could 
affect protein function.
DISCUSSION
MDS have been recognized as acquired genetic dis-
orders and several genetic and epigenetic mecha-
nisms have been pointed out as important for their 
etiology, but the molecular pathogenesis of MDS is 
still uncertain. 
MDS are also characterized by an increased risk 
of developing acute myeloid leukemia (AML), thus 
indicating that MDS may represent a step in the ev-
olution of AML. Additionally, AML and MDS have 
several features in common, such as some similar 
molecular lesions observed in both diseases. Hence, 
data obtained from AML cases may be a starting 
points for the elucidation of MDS.  
The most common molecular alteration in AML 
is mutations of the NPM1 gene (Gaidzik and Dohn-
er, 2008). The NPM1 encodes for nucleophosmin 
(NPM), a member of the family of chaperones pre-
dominantly found in the granular regions of nucle-
oli. Both tumor-suppressive and oncogenic features 
have been attributed to this protein. NPM has several 
domains that are crucial for its functions and one of 
these is a C-terminal nucleic acid-binding domain 
involved in ribosomal RNA processing (Hingorani 
et al., 2000) and for the nucleolar localization of nu-
cleophosmin. 
Mutations in exon 12 of the NPM1 gene repre-
sent the most frequent molecular alterations in adult 
patients with acute myeloid leukemia  (AML), de-
tected in one third of all AML cases (Thiede et al., 
2006). In AML patients with a normal karyotype the 
frequency of NPM1 mutations is even higher and 
ranges from 45.7% to 63.8% (Chou et al., 2006; Su-
zuki et al., 2005). In childhood AML, these molecu-
lar events are less common and are detected in 2.1% 
(Chou et al., 2006), 6.5% (Cazzaniga et al., 2005), 8% 
(Brown et al., 2007) and 12% (Thiede et al., 2007) of 
all AML cases. Similarly to adult patients, in a karyo-
typically normal pediatric AML the occurrence of 
NPM1 mutations is higher, accounting for 9% to 
26.9% of cases. Only heterozygous NPM1 mutations 
have been found so far. 
Mutations of the nucleophosmin gene have been 
identified in 5.2% (2/38) of adults with MDS (Zhang 
et al., 2007). The detected mutations were of the 
same type and effects as the NPM1 mutations found 
in AML. 
We evaluated the prevalence of NPM1 mutations 
in a group of 17 pediatric MDS patients. The NPM1 
mutation was detected in one case. To our knowl-
edge, this is the first report of NPM1 mutation in 
childhood MDS.
All AML-related mutations of the NPM1 gene 
result in an insertion or an insertion associated with 
deletion. Despite genetic heterogeneity, all variants 
generate a frame shift in the region encoding for 
Fig. 1 Sequencing of a DNA sample from a patient with a muta-
tion (transition T to C). The arrow indicates the position of the 
mutation.
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the C-terminus of NPM protein resulting in the re-
placement of the last 7 amino acids (WQWRKSL) 
(Falini et al., 2006). Disruption of NPM1 results in 
the generation of an additional leucine-rich nuclear 
exporting signal (NES) motif (Falini et al., 2006) 
and the loss of tryptophan residues 288 and 290 
(Falini et al., 2005). As a consequence, nucleophos-
min is dislocated and accumulated in the cytoplasm 
(Falini et al., 2007a) where it cannot execute its nor-
mal function. 
The mutation detected in this study disrupts the 
same WQWRKSL protein sequence, but the type of 
mutation is the transition C to T in codon 293 that 
changes serine to proline. 
This is the very first missense mutation of the 
NPM1 gene reported so far. Our data may indicate 
that disruption of NPM has different roles in the 
evolution of MDS, comparable with AML. A Falini’s 
immunohistochemical study, which showed on 50 
patients with MDS only nucleus-restricted NPM ex-
pression (Falini et al., 2007b), favored the hypothesis 
that additional mechanisms, other than frameshift 
mutations, could be involved in the pathogenic role 
of NPM in MDS. 
Although S293P substitution affects nucleophos-
min functions according to all prediction programs, 
the interpretation of these predictions must be care-
fully correlated with the clinical impact in MDS. Pre-
diction methods are not able to consider posttrans-
lational modifications of the protein, as well as inter-
actions with other molecules involved in cell cycle 
control. Hence, the effects of this mutation remain 
to be explored.
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